Casopitant

From Self-sufficiency
Revision as of 14:47, 29 July 2010 by PotatoBot (Talk) (Stub sorting and placement of stub template(s))

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Casopitant
220px
Systematic (IUPAC) name
(2S,4S)-4-(4-Acetyl-1-piperazinyl)-N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-N-methyl-1-piperidinecarboxamide
Identifiers
ATC code A04AD13 (WHO)
PubChem CID 23725089
Chemical data
Formula C30H35F7N4O2
Molar mass 616.26 g/mol[[Script error: No such module "String".]]
Script error: No such module "collapsible list".
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Casopitant (trade names Rezonic (US), Zunrisa (EU)) is an neurokinin 1 (NK1) receptor antagonist undergoing research for the treatment of chemotherapy-induced nausea and vomiting (CINV).[1] It is currently under development by GlaxoSmithKline (GSK).

In July 2008, the company filed a marketing authorisation application with the European Medicines Agency. The application was withdrawn in September 2009 because GSK decided that further safety assessment was necessary.[2]

See also

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />


5-HT3 Antagonists
CB1 Agonists (Cannabinoids)
D2/D3 Antagonists
H1 Antagonists (Antihistamines)
mACh Antagonists (Anticholinergics)
NK1 Antagonists
Others
GABAA PAMs
Others
α2δ VDCC Blockers
5-HT1A Agonists
Azapirones: Buspirone • Gepirone • Tandospirone; Others: Flesinoxan • Oxaflozane
H1 Antagonists
Diphenylmethanes: Captodiame • Hydroxyzine; Others: Brompheniramine • Chlorpheniramine • Pheniramine
CRH1 Antagonists
NK2 Antagonists
MCH1 antagonists
mGluR2/3 Agonists
mGluR5 NAMs
TSPO agonists
σ1 agonists
Others

M: PSO/PSI

dsrd (o, p, m, p, a, d, s), sysi/epon, spvo

proc, drug(N5A/5B/5C/6A/6B/6D)


45px This drug article relating to the gastrointestinal system is a stub. You can help ssf by expanding it.
35px This drug article relating to the nervous system is a stub. You can help ssf by expanding it.
  1. ↑ Lohr L (2008). "Chemotherapy-induced nausea and vomiting". Cancer J. 14 (2): 85–93. doi:10.1097/PPO.0b013e31816a0f07. PMID 18391612. 
  2. ↑ "GlaxoSmithKline withdraws its marketing authorisation application for Zunrisa" (PDF). London: EMEA. 13 October 2009. Retrieved 21 December 2009. 
Retrieved from "http://ssf.f15ijp.com/wiki/index.php?title=Casopitant&oldid=24215"